PREVAIL TRANSAPICAL: multicentre trial of transcatheter aortic valve implantation using the newly designed bioprosthesis (SAPIEN-XT) and delivery system (ASCENDRA-II)
Key result
Transapical aortic valve implantation using the SAPIEN XT prosthesis in high-risk patients demonstrated good functionality with an 8.7% 30-day mortality rate.
Population
150 high-risk elderly patients undergoing transapical aortic valve implantation, mean age 81.6, 40.7%…
Design
Cohort
Follow-up
30 days
Authors
Discussion
Loading...
Member takes
Implication
Supports feasibility in high-risk patients; leaves open randomized trials versus alternative access routes.
Structured PICO
P
Population
150 high-risk elderly patients (mean age 81.6 years, 40.7% female) undergoing transapical aortic valve implantation, evaluated at 30 days.
I
Intervention
Transapical aortic valve implantation (TA-AVI) using the second-generation SAPIEN XT prosthesis (23 mm, 26 mm, or 29 mm) and ASCENDRA-II delivery system.
O
Outcome
30-day mortality, postoperative complications, and echocardiographic valve function at dischargehard clinical
Transapical aortic valve implantation using the SAPIEN XT prosthesis and ASCENDRA-II delivery system is feasible and shows acceptable 30-day outcomes in high-risk elderly patients.
Cite This Study
Walther et al. (2012) studied Aortic valve disease requiring implantation (n=150). Transapical aortic valve implantation (SAPIEN XT prosthesis and ASCENDRA-II delivery system) was evaluated on 30-day mortality. Transapical aortic valve implantation using the SAPIEN XT prosthesis in high-risk patients demonstrated good functionality with an 8.7% 30-day mortality rate.